Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme.
The implementation of an antenatal screening programme for neonatal alloimmune thrombocytopenia (NAIT) is currently under debate. We evaluated the detection rate for NAIT in a nonscreened population of 661,200 births where NAIT was diagnosed on clinical indication. We did a cross-sectional comparison with a population of 100,448 human platelet antigen 1a (HPA1a)-screened pregnancies from three of the five health regions in Norway. In a nonscreening situation, 7.5 cases of NAIT were detected per year compared with 53 cases when screening was applied. The detection rate of NAIT in Norway was therefore 14% of the expected rate.
Tiller
H
H
Department of Immunology and Transfusion Medicine, University Hospital of North Norway, Tromsø, Norway. heidi.tiller@unn.no
Killie
M K
MK
Skogen
B
B
Øian
P
P
Husebekk
A
A
D016824:Antigens, Human Platelet / Q000097:blood*; D003430:Cross-Sectional Studies; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D039661:Integrin beta3; D009664:Norway / Q000453:epidemiology; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D054098:Thrombocytopenia, Neonatal Alloimmune / Q000175:diagnosis* / Q000453:epidemiology
D016824:Antigens, Human Platelet; C061248:ITGB3 protein, human; D039661:Integrin beta3